CY1114734T1 - Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης - Google Patents

Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης

Info

Publication number
CY1114734T1
CY1114734T1 CY20131101162T CY131101162T CY1114734T1 CY 1114734 T1 CY1114734 T1 CY 1114734T1 CY 20131101162 T CY20131101162 T CY 20131101162T CY 131101162 T CY131101162 T CY 131101162T CY 1114734 T1 CY1114734 T1 CY 1114734T1
Authority
CY
Cyprus
Prior art keywords
vascular
adjustment
pharmaceutical compositions
methods used
mammalian tissue
Prior art date
Application number
CY20131101162T
Other languages
English (en)
Inventor
Gera Neufeld
Gal Akiri
Zahava Vadasz
Stela Gengrovitch
Original Assignee
Technion Research And Development Foundation, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation, Ltd. filed Critical Technion Research And Development Foundation, Ltd.
Publication of CY1114734T1 publication Critical patent/CY1114734T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Παρέχεται μέθοδος ρύθμισης αγγειογένεσης σε έναν ιστό θηλαστικού. Η μέθοδος περιλαμβάνει χορήγηση εντός του ιστού θηλαστικού ενός μορίου ικανού τροποποίησης επιπέδου ιστού ή/και δραστικότητας τουλάχιστον ενός τύπου λυσύλοξειδάσης για να ρυθμίζεται με τον τρόπο αυτό αγγειογένεση στον ιστό θηλαστικού.
CY20131101162T 2000-08-08 2013-12-23 Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης CY1114734T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08
EP10012457.7A EP2359853B1 (en) 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for modulating angiogenesis

Publications (1)

Publication Number Publication Date
CY1114734T1 true CY1114734T1 (el) 2016-12-14

Family

ID=22837793

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100336T CY1111869T1 (el) 2000-08-08 2011-03-29 Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για την αντιμετωπιση του καρκινου ή της ηπατικης ινωσης
CY20121100746T CY1113142T1 (el) 2000-08-08 2012-08-21 Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμοι για τη διαμορφωση της αγγειογενεσης
CY20131101162T CY1114734T1 (el) 2000-08-08 2013-12-23 Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111100336T CY1111869T1 (el) 2000-08-08 2011-03-29 Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για την αντιμετωπιση του καρκινου ή της ηπατικης ινωσης
CY20121100746T CY1113142T1 (el) 2000-08-08 2012-08-21 Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμοι για τη διαμορφωση της αγγειογενεσης

Country Status (10)

Country Link
EP (4) EP2078531B1 (el)
AT (1) ATE493147T1 (el)
AU (1) AU2001280056A1 (el)
CY (3) CY1111869T1 (el)
DE (1) DE60143754D1 (el)
DK (4) DK2078531T3 (el)
ES (4) ES2440932T3 (el)
HK (3) HK1131912A1 (el)
PT (4) PT2359854E (el)
WO (1) WO2002011667A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
FR2855968B1 (fr) * 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
JP2007526247A (ja) 2004-01-23 2007-09-13 マサチューセッツ・アイ・アンド・イア・インファーマリー リジルオキシダーゼ様１（ｌｏｘｌ１）および弾性繊維形成
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
JP5312459B2 (ja) 2007-08-02 2013-10-09 ジリード バイオロジクス，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
DE102007051006A1 (de) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stabile, synergistische Mischungen
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
AU2010284036B2 (en) 2009-08-21 2014-12-18 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
SG183174A1 (en) 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
WO2001083702A2 (en) * 2000-05-03 2001-11-08 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
EP2359853B1 (en) 2013-11-06
DK1315519T3 (da) 2011-04-11
ES2437093T3 (es) 2014-01-08
ATE493147T1 (de) 2011-01-15
CY1111869T1 (el) 2015-11-04
EP1315519A2 (en) 2003-06-04
EP2078531A3 (en) 2010-01-20
EP2359854B1 (en) 2013-10-09
EP2359854A1 (en) 2011-08-24
HK1161113A1 (en) 2012-08-24
ES2440932T3 (es) 2014-01-31
CY1113142T1 (el) 2016-04-13
EP2359853A1 (en) 2011-08-24
HK1161115A1 (en) 2012-08-24
PT2078531E (pt) 2012-08-06
DE60143754D1 (de) 2011-02-10
PT2359854E (pt) 2013-11-22
PT2359853E (pt) 2013-12-26
ES2387329T3 (es) 2012-09-20
EP2078531A2 (en) 2009-07-15
ES2358581T3 (es) 2011-05-12
PT1315519E (pt) 2011-03-17
HK1131912A1 (en) 2010-02-12
DK2078531T3 (da) 2012-09-10
EP1315519A4 (en) 2005-09-14
WO2002011667A3 (en) 2003-03-27
AU2001280056A1 (en) 2002-02-18
DK2359854T3 (da) 2013-11-04
EP2078531B1 (en) 2012-05-30
EP1315519B1 (en) 2010-12-29
WO2002011667A2 (en) 2002-02-14
DK2359853T3 (da) 2013-12-09

Similar Documents

Publication Publication Date Title
CY1114734T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης
KR890000101A (ko) 반월조직의 치료 개선방법 및 치료약제
DE69023574D1 (de) Amphotere Zusammensetzungen und Polymerformen von alpha-Hydroxy-Säuren, und ihre therapeutische Anwendung.
SE9101853D0 (sv) Improved tissue ashesive
BR9807816A (pt) Permeação anestésica tópica assistida a laser
BR9403783A (pt) Uso de uma composição cosmética
ATE283695T1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DE69615984T2 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
DE59509395D1 (de) Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
DE69625918D1 (de) Lang wirksames mittel zur rektalen verabreichung
ATE120962T1 (de) Antithrombin-lösung und ihre verwendung.
ES2059588T3 (es) Factor xiii para la prevencion de una hemorragia intraventricular.
ATE95421T1 (de) Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
ATE56147T1 (de) T-pa enthaltende medizinische zubereitung und deren verwendung.
ES2077698T3 (es) Agente terapeutico para la gangrena diabetica.
CY1114741T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες στη διαμορφωση της αγγειογενεσης
ATE188384T1 (de) Verwendung von kollagen zur behandlung von krankhaften gelenkprozessen